Occult hepatitis B virus infection in a North American adult hemodialysis patient population

Hepatitis B virus (HBV) infections continue to occur in adult hemodialysis units. A possible contributing factor is the presence of occult HBV (serum hepatitis B surface antigen [HBsAg] negative but HBV DNA positive). Two hundred forty‐one adult hemodialysis patients were screened for occult HBV. HBV DNA testing was performed by real‐time polymerase chain reaction (PCR) with 2 independent primer sets (core promoter and surface). Two (0.8%) of the 241 patients were HBsAg positive. Of the remaining 239 HBsAg‐negative patients, 9 (3.8%) were HBV DNA positive. Viral loads in these individuals were low (102‐104 viral copies/mL). Seven of the 9 (78%) were nt 587 mutation (sG145R mutant) positive. Demographic, biochemical, and HBV serological testing did not help to identify those with occult HBV. In conclusion, the prevalence of occult HBV in adult hemodialysis patients in this North American urban center is approximately 4 to 5 times higher than standard HBsAg testing would suggest. The majority of these infections are associated with low viral loads and a high prevalence of the sG145R mutant. Finally, the demographic, biochemical, and/or serological features of HBV DNA–positive subjects do not distinguish these individuals from the remainder of the dialysis patient population. (HEPATOLOGY 2004; 40:1072–1077.)

[1]  F. Zoulim,et al.  Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays , 2004, Journal of medical virology.

[2]  M. Alter,et al.  National surveillance of dialysis-associated diseases in the United States, 2001. , 2004, Seminars in dialysis.

[3]  J. Desenclos,et al.  Six years of sentinel surveillance of hepatitis B in general practice in France , 1998, European Journal of Epidemiology.

[4]  Manna Zhang,et al.  Rapid detection of hepatitis B virus mutations using real‐time PCR and melting curve analysis , 2002, Hepatology.

[5]  J. Marrugat,et al.  Prevalencia de las hepatitis B y C en diversas comarcas de Cataluña: estudio transversal , 2002 .

[6]  R. Solà,et al.  Prevalence of hepatitis B and hepatitis C viruses in different counties of Catalonia, Spain: cross-sectional study: cross-sectional study , 2002 .

[7]  G. Minuk,et al.  Chronic hepatitis B infection in Canada. , 2001, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.

[8]  G. Lau,et al.  Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen–negative Chinese carriers , 2001, Hepatology.

[9]  M. Alter,et al.  Infection control in hemodialysis units. , 2001, Infectious disease clinics of North America.

[10]  C. Bréchot,et al.  Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely “occult”? , 2001, Hepatology.

[11]  U. Binswanger,et al.  [Epidemiology of chronic hepatitis B and C among dialysis patients in Switzerland]. , 2000, Schweizerische medizinische Wochenschrift.

[12]  S. Locarnini,et al.  Antiviral chemotherapy for the treatment of hepatitis B virus infections. , 2000, Gastroenterology.

[13]  H. Marusawa,et al.  Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. , 1998, Transplantation.

[14]  A. Lok,et al.  Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis , 1998, Hepatology.

[15]  M. Alter,et al.  National surveillance of dialysis associated diseases in the United States, 1995. , 1998, ASAIO journal.

[16]  R. Wiesner,et al.  Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. , 1997, Gastroenterology.

[17]  J. Bartolomé,et al.  Hepatitis B virus DNA in serum and blood cells of hepatitis B surface antigen-negative hemodialysis patients and staff. , 1997, Journal of the American Society of Nephrology : JASN.

[18]  D. Samuel,et al.  De novo and apparent de novo hepatitis B virus infection after liver transplantation. , 1997, Journal of hepatology.

[19]  M. Sata,et al.  Detection of serum HBV DNA and anti-HCV antibody in HBsAg seronegative patients with hepatocellular carcinoma in Japan. , 1996, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases.

[20]  G. Sunder-Plassmann,et al.  HBV and HCV genome in peripheral blood mononuclear cells in patients undergoing chronic hemodialysis. , 1995, Kidney international.

[21]  J. Emond,et al.  The Risk Of Transmission Of Hepatitis B From Hbsag(-), Hbcab(+), Hbigm(-) Organ Donors , 1995, Transplantation.

[22]  H. Okamoto,et al.  Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen , 1994, Journal of virology.

[23]  L. Ferrell,et al.  "Occult" hepatitis B virus as source of infection in liver transplant recipients , 1994, The Lancet.

[24]  P. Grob,et al.  Detection of HBs antigen in "anti-HBc alone" positive sera. , 1994, Journal of hepatology.

[25]  I. Lauder,et al.  A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. , 1992, Gastroenterology.

[26]  J. Sninsky,et al.  Transmission of serologically silent hepatitis B virus along with hepatitis C virus in two cases of posttransfusion hepatitis , 1992, Transfusion.

[27]  M. Alter,et al.  Hemodialysis‐Associated Hepatitis B: Revised Recommendations for Serologic Screening , 1990 .

[28]  A. Zuckerman,et al.  Vaccine-induced escape mutant of hepatitis B virus , 1990, The Lancet.

[29]  K. Isselbacher,et al.  Rapid identification of low level hepatitis B-related viral genome in serum. , 1989, The Journal of clinical investigation.

[30]  C. Bréchot,et al.  TRANSMISSION OF HEPATITIS B FROM HEPATITIS-B-SERONEGATIVE SUBJECTS , 1988, The Lancet.

[31]  K. Isselbacher,et al.  Detection of hepatitis B virus infection in hepatitis B surface antigen-negative hemodialysis patients by monoclonal radioimmunoassays. , 1986, Gastroenterology.

[32]  K. Isselbacher,et al.  Identification and transmission of hepatitis B virus-related variants. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[33]  W. Szmuness,et al.  Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. , 1984, The New England journal of medicine.

[34]  M. Alter,et al.  Cost benefit of vaccination for hepatitis B in hemodialysis centers. , 1983, The Journal of infectious diseases.

[35]  H. Conn,et al.  Observations on decreased serum glutamic oxalacetic transaminase (SGOT) activity in azotemic patients. , 1976, Annals of internal medicine.